You just read:

Ibrutinib (IMBRUVICA ®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia

News provided by

Janssen Inc.

Jun 03, 2015, 07:59 ET